The difference in findings may also have occurred for other reasons, such as differences in patient populations (eg, the inclusion of only patients with lymph node–negative, ER-positive/ERBB2-negative breast cancer in the present analysis) or differences by treatment.2,16. This evidence concerns the gene ERBB2 and breast carcinoma.